Back

The effect of sacubitril/valsartan on functional disability and skeletal muscle injury during breast cancer therapy: insights from the PRADA II trial

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Prevention and early detection of cardiovascular toxicity in patients with cancer and cancer survivors Cardio-Oncology ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Victoria Vinje

Akershus University Hospital - AHUS, Nordbyhagen (Norway)

5 More presentations in this session

Presentation thumbnail
Effects of sacubitril/valsartan on left and right ventricular function during and after breast cancer therapy: a randomised placebo-controlled trial
Mrs M. Gynnild (Trondheim, NO)
Abstract Slides Video
Presentation thumbnail
Baseline left atrial reservoir strain predicts subclinical left ventricular dysfunction in breast cancer patients undergoing chemotherapy
Doctor P. Martinez-Dominguez (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Cardiac irradiation is associated with early diastolic impairment after contemporary radiotherapy
Doctor F. Haga (Fukushima, JP)
Abstract Slides Video
Presentation thumbnail
Early multi-chamber atrial dysfunction as a marker of subclinical cardiotoxicity in breast cancer patients: a prospective 2D speckle-tracking study
Associate Professor E. Allouche (Tunis, TN)
Abstract Slides Video
Presentation thumbnail
Myocardial work derived from myocardial stiffness and strain in childhood cancer survivors treated with high-dose anthracycline chemotherapy
Doctor L. Zanella (Bologna, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention and early detection of cardiovascular toxicity in patients with cancer and cancer survivors

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Sacubitril/valsartan in primary prevention of cancer-therapy related cardiac dysfunction in breast cancer patients.
1 September 2024
thumbnail
Congress Presentation
Ivabradine for prevention of anthracycline-induced cardiotoxicity: a systematic review and meta-analysis
31 August 2025
thumbnail
Congress Presentation
Cardiopulmonary fitness and cancer therapy-related cardiac dysfunction defined by CMR: insights from the EMBRACE-MRI study
28 August 2026
thumbnail
Congress Presentation
Prognostic value of domain-specific changes in physical function in frail older patients with heart failure
29 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources